Showing 3691-3700 of 7027 results for "".
- UCB Anticipates Delay for FDA Bimekizumab Decisionhttps://practicaldermatology.com/news/ucb-anticipates-delay-for-fda-bimekizumab-decision/2462017/The anticipated Biologics License Application (BLA) for bimekizumab to treat plaque psoriasis will likely be delayed beyond Q3 2023, according to a statement from UCB. Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) an
- Exploring the Link Between Sex Hormones and Melanoma Riskhttps://practicaldermatology.com/news/exploring-the-link-between-sex-hormones-and-melanoma-risk/2462016/Researchers out of the University of Tennessee Health Science Center are beginning a study to determine whether sex hormones affect the risk of melanoma The team received a $423,500 grant from the National Institute of Environmental Health Sciences, part of the National Institutes of He
- MTX vs. CsA in AD: Which Is Best for Kids?https://practicaldermatology.com/news/mtx-vs-csa-in-ad-which-is-best-for-kids/2462008/Methotrexate bested cyclosporine in children with severe atopic dermatitis, a new study shows. While new systemic therapies for AD are being introduced, researchers want to est
- Innovation in Action: A Newly Developed Anti-bacterial Silver Gel May Best Other Silver-based Drugshttps://practicaldermatology.com/news/innovation-in-action-a-newly-developed-anti-bacterial-silver-gel-may-best-other-silver-based-drugs/2461999/A new anti-bacterial gel based on silver and sulfur-containing amino acids may be one hundred times more effective than other silver-based antibacterials, according to research in the Journal of Material
- Biosimilar News: Samsung Bioepis, Sandoz to Develop SB17, a Proposed Stelara Biosimilar to Stelarahttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-sandoz-to-develop-sb17-a-proposed-stelara-biosimilar-to-stelara/2461991/Samsung Bioepis Co., Ltd. has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelara (ustekinumab). Samsung Bioepis will be responsible for development, regulatory registration and manufacture and supply of the product in t
- ICYMI: Vaseline, CVS Partner to Bridge the Gap of Skin Care Inequities in People of Colorhttps://practicaldermatology.com/news/icymi-vaseline-cvs-partner-to-bridge-the-gap-of-skin-care-inequities-in-people-of-color/2461988/Vaseline’s recent Train the Trainer webinar helped educate CVS field leaders on the skin care inequities that exist for Black and Brown populations as part of the brand’s ongoing partnership with CVS Health. During the webcast, Boston area-based dermatologi
- Tarsus Rolls Out XDEMVY for Demodex Blepharitishttps://practicaldermatology.com/news/tarsus-rolls-out-xdemvy-for-demodex-blepharitis/2461985/Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis. XDEMVY is now available at pharmacies nationwide for prescription. Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, ran
- Regenerative Medicine in Action: Scarless Wound Recovery May Be Possible with New Autologous Blood Techniquehttps://practicaldermatology.com/news/regenerative-medicine-in-action-scarless-wound-recovery-may-be-possible-with-new-autologous-blood-technique/2461982/A new technology that utilizes autologous blood to produce three-dimensional microvascular implants may help make scarless wound recovery a reality. Led by Professor Joo H. Kang from the Department of Biomedical Engineering at UNIST, the team developed a microfluidic system capable
- TikTok Trend Watch: Is Beer Tanning Really a Thing?https://practicaldermatology.com/news/tik-tok-trend-watch-is-beer-tanning-really-a-thing/2461976/TikTok is where many trends and DIY challenges get started, and skincare is one of the more popular categories for this content, for better or sometimes for worse. Take beer tanning, for example. Tik Tokkers are claiming that pouring beer on skin will activate melanin for a better
- Christopher G. Bunick, MD, PhD, Receives the American Acne and Rosacea Society's 2023 Research Scholar Awardhttps://practicaldermatology.com/news/christopher-g-bunick-md-phd-receives-american-acne-and-rosacea-society-announces-2023-research-scholar-award/2461962/Christopher G. Bunick, MD, PhD, has received The American Acne and Rosacea Society’s (AARS) 2023 Research Scholar Award. Dr. Bunick is an Associate Professor of Dermatology at Yale University School of Medicine and a member of the Practical Dermatology magazine editorial board.</